Extract
Patients with severe asthma often do not experience sufficient disease control or, if they do, only at the expense of significant side-effects related to high oral corticosteroid (OCS) use. Biologics have changed the management of severe asthma by offering multiple therapeutic options targeting IgE, interleukin (IL)-4Ra/IL-13, IL-5/5Ra, thymic stromal lymphopoietin (TSLP) and related pathways. Soon, more (upstream) biologics are expected to follow. However, these opportunities also pose new challenges for physicians and the healthcare system. Considerable costs demand that treatment response in patients with severe asthma is well defined by accepted Core Outcome Measures (COM).
Abstract
The COMSA consensus document is a big step forward to serve the demand for harmonised patient-centred COM sets for severe asthma treatment by including all relevant stakeholders http://bit.ly/3UR4rge
Footnotes
Conflict of interest: T. Eiwegger reports to act/recently acted as local PI for company sponsored trials by DBV Therapeutics and Greer Stallergens, and as sub-investigator for Regeneron and ALK-Abelló. He/his lab received unconditional/in-kind contributions from Macro Array Diagnostics and ALK-Abelló and he is co-investigator in an investigator-initiated trial with in-kind support from Novartis. He holds advisory board roles for ALK-Abelló, and Aimmune, and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, ALK-Abelló and Novartis. S.A. Bendien reports lecture fees from AstraZeneca, GSK, Teva and Sanofi.
- Received October 25, 2022.
- Accepted November 4, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org